Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients

Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients

Coronavirus disease 2019 (COVID-19) is a highly infectious respiratory disease caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has been observed to vary in its degree of symptoms. One of the most important clinical manifestations is pneumonia...

Full description

Bibliographic Details
Main Authors: Bogna Grygiel-Górniak, Osama Shaikh, Nikita Niranjan Kumar, Shao Heng Hsu, Włodzimierz Samborski
Format: Article
Language:English
Published: Termedia Publishing House 2021-08-01
Series:Rheumatology
Subjects:
rheumatic diseases
tocilizumab
coronavirus disease 2019.
Online Access:https://www.termedia.pl/Use-of-the-rheumatic-drug-tocilizumab-for-treatment-of-SARS-CoV-2-patients,18,44953,1,1.html

Internet

https://www.termedia.pl/Use-of-the-rheumatic-drug-tocilizumab-for-treatment-of-SARS-CoV-2-patients,18,44953,1,1.html

Similar Items